Related introduction of Wayrilz (Rilzabrutinib): What is it a medicine for?

Wayrilz (Rilzabrutinib) is a new prescription medicine indicated for the treatment of persistent or chronic immune thrombocytopenia (ITP) in adults who have not responded to earlier treatments. ITP is an autoimmune disease in which the patient's immune system mistakenly attacks and destroys the patient's own platelets, resulting in a reduced number of platelets, which negatively affects coagulation function. Wayrilz, an oral reversible Bruton's tyrosine kinase (BTK) inhibitor, can target the root cause of ITP and effectively improve platelet counts and other related symptoms.

The mechanism of action of Wayrilz is mainly by inhibiting the activation of B cells, reducing the production of autoantibodies against platelets, and by blocking the phagocytosis of Fcγ receptor (FcγR) antibody-coated cells in the spleen and liver, thereby reducing the destruction of platelets. This unique mechanism allows Wayrilz to show good results in improving the clinical symptoms of ITP patients.

According to the FDA approval obtained on August 29, 2025, the safety and efficacy of Wayrilz were verified in the LUNA Phase III clinical trial (NCT04562766). Trial results showed that Wayrilz was able to significantly increase sustained platelet counts and improve other symptoms associated with ITP. To improve the tolerability of the drug, the recommended dose is 400 mg taken orally twice daily. Patients may consider taking it with food, especially those with gastrointestinal symptoms. Additionally, patients should swallow the pills whole with a glass of water and never cut, crush, or chew the pills.

Despite its effectivenessWayrilz may increase the risk of serious infections (including bacterial, viral or fungal). Common side effects include diarrhea, nausea, headache, abdominal pain, and COVID-19. In summary, Wayrilz, as a new BTK inhibitor, provides a new option for the treatment of immune thrombocytopenia, especially for patients who have poor response to traditional treatments, and its clinical application prospects are broad.

Reference materials:https://go.drugbank.com/drugs/DB17709